Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Hifibio Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are being reviewed by 2 distinct examiners, showing a one-to-one ratio of pending actions to examiners. Furthermore, the portfolio is active across 2 distinct art units, which indicates that each pending action is likely situated in a different technical niche.
STEPHENS, AMELIA CAROLE is identified as the busiest examiner, with 1 busiest examiner pending office action. Given that there are 2 pending office actions in total, this examiner is responsible for half of the current pending workload. The other 1 pending office action is managed by the second of the 2 distinct examiners.
The distribution across 2 distinct art units means that practitioners must navigate the procedural nuances of two different sections of the office. With 2 distinct examiners involved, the company faces two independent sets of examiner preferences. Monitoring the 1 busiest examiner pending office action assigned to STEPHENS, AMELIA CAROLE is essential for managing the current prosecution pipeline effectively.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| LU, CHENG | 1 | 54.1% | +64.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572710 | ANTI-OX40 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF | STEPHENS, AMELIA CAROLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572710 | ANTI-OX40 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF | STEPHENS, AMELIA CAROLE | — |
| 18280927 | ANTI-HUMAN CXCR5 ANTIBODY AND USES THEREOF | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572710 | ANTI-OX40 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18280927 | ANTI-HUMAN CXCR5 ANTIBODY AND USES THEREOF | LU, CHENG | 1642 | §102§103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial